MT-ND4
ENSG00000198886
Chromosome
Mitochondrial
- ClinGen gene-disease validity
- Definitive
- Chemical probe available
- Yes
- Target name
- MT-ND4
- Gene name
- Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4
- Gene symbol
- MT-ND4
- Protein name
- Mitochondrial alternative ND4 protein (MTALTND4)
- ND4
- NAD4
- MTND4
- LHON
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Mitochondrially encoded protein coding genes
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 66,015.7
- Tissue specificity (Gini)
- 0.244
- Tissue specificity (tau)
- 0.463
- Protein interaction confidence
- 0.931147
- Protein interaction partners
- 109
- End position
- 12137
- Start position
- 10760
- Chromosome
- Mitochondrial
- Strand
- Forward
- Secreted . Cytoplasm . Mitochondrion .
- Mitochondria
Publication evidence
- PubMed 37198654
- Tissue specificity (tau)
- 0.463047
- Expression inequality (Gini)
- 0.243657
Expression in transcripts per million
- Heart - Left Ventricle
- 66,015.7
- Kidney - Cortex
- 60,767.6
- Brain - Hippocampus
- 60,340.2
- Liver
- 58,775.3
- Brain - Putamen (basal ganglia)
- 58,398.3
Expression in transcripts per million
- Heart - Left Ventricle66,015.7
- Kidney - Cortex60,767.6
- Brain - Hippocampus60,340.2
- Liver58,775.3
- Brain - Putamen (basal ganglia)58,398.3
- Brain - Amygdala56,265.9
- Brain - Hypothalamus55,126.2
- Brain - Caudate (basal ganglia)55,054.5
- Heart - Atrial Appendage54,795.8
- Brain - Anterior cingulate cortex (BA24)54,329.2
- Adrenal Gland54,001.3
- Brain - Cortex53,710.3
- Brain - Substantia nigra52,826.4
- Brain - Nucleus accumbens (basal ganglia)52,609.3
- Brain - Spinal cord (cervical c-1)47,076.5
- Kidney - Medulla46,599.2
- Brain - Frontal Cortex (BA9)44,700.9
- Stomach44,214.7
- Brain - Cerebellum41,553.3
- Colon - Transverse40,944.8
- Muscle - Skeletal40,765.5
- Esophagus - Muscularis40,098.1
- Prostate39,242.2
- Esophagus - Gastroesophageal Junction38,249.9
- Small Intestine - Terminal Ileum37,438.9
And 29 more, listed on the interactive page.
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor